Diagnostic Testing and Treatment Guidelines for COVID-19 and Influenza

Webinar

View slides
View transcript

Free Continuing Education

Overview

Diagnostic testing for SARS-CoV-2 and influenza viruses can guide clinical management, including appropriate antiviral treatment, particularly in persons at higher risk for progression to severe disease from COVID-19 and influenza, regardless of vaccination status. Antivirals are available that can reduce the risk of severe illness and death from COVID-19 and mitigate influenza illness. During this COCA Call, subject matter experts will present an overview of COVID-19 and influenza therapeutic options, including eligibility, indications, and efficacy.

Presenters

Pragna Patel, MD, MPH
Chief Medical Officer
Coronavirus and Other Respiratory Viruses Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention

Tim Uyeki, MD, MPH, MPP
Chief Medical Officer
Influenza Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention

Call Objectives

COCA Call Objectives

At the conclusion of the session, the participant will be able to accomplish the following:

1. Cite background information on the topic covered during the presentation.
2. Discuss CDC's role in the topic covered during the presentation.
3. Describe the topic's implications for clinicians.
4. Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
5. Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers.

Activity-Specific Objectives

1. List available tests and when to test for SARS-CoV-2 and influenza viruses, including indications for repeat testing.
2. Describe recommended antivirals for treating influenza and COVID-19 and clinical benefits.
3. Cite factors for deciding who to treat for COVID-19 and influenza.
4. Review indications for empiric treatment of influenza and COVID-19.

Additional Resources

Influenza

• Influenza Antiviral Medications: Summary for Clinicians
• Information for Health Professionals: Influenza Antiviral Medications
• Information for Clinicians on Influenza Virus Testing
• Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza
• ACIP Recommendations Summary | Influenza (Flu) | CDC
• Weekly U.S. Influenza Surveillance Report

COVID-19

• Interim Clinical Considerations for COVID-19 Treatment in Outpatients
• COVID-19 Clinical Course: Progression, Management, and Treatment
• COVID-19 Special Clinical Considerations
• Guidance for Healthcare Workers about COVID-19 (SARS-CoV-2) Testing
• COVID-19 Data & Surveillance
• Treatment Options for COVID19 | HHS/ASPR
• ASPR COVID-19 therapeutics commercialization transition guide
• FDA COVID-19 therapeutics
• Test to Treat
• COVID-19 Therapeutics Locator
• Resources to Prepare for Flu, COVID-19, and RSV | CDC
• Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 1) | Annals of Internal Medicine (acpjournals.org)
• Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 2) | Annals of Internal Medicine (acpjournals.org)

Continuing Education

Instructions for Obtaining Continuing Education (CE)

To receive continuing education (CE) for WC4520R—Diagnostic Testing and Treatment Guidelines for COVID-19 and Influenza—please visit CDC TRAIN and search for the course in the Course Catalog using WC4520R-020124. Follow the steps below by March 4, 2024.

To receive continuing education (CE) for WD4520R—Diagnostic Testing and Treatment Guidelines for COVID-19 and Influenza—please visit CDC TRAIN and search for the course in the Course Catalog using WD4520R-020124. Follow the steps below between March 5, 2024, and March 5, 2026.

1. Register for and complete the course.
2. Pass the post-assessment at 75%.
3. Complete the evaluation.
4. Visit Your Learning to access your certificates and transcript.

Accreditation Statements

In support of improving patient care, The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME: The Centers for Disease Control and Prevention designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA CME: Credit Designation Statement – Live
The Centers for Disease Control and Prevention has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

CNE: The Centers for Disease Control and Prevention designates this activity for 1 nursing contact hours.

CPE: The Centers for Disease Control and Prevention designated this Knowledge-based event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is JA4008229-0000-24-015-L04-P and enduring JA4008229-0000-24-016-H04-P.

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU's for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES^®) and/or Master Certified Health Education Specialists (MCHES^®) to receive up to 1 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 1. Continuing Competency credits available are 1. CDC provider number 98614.

AAVSB/RACE: This program has been submitted (but not yet approved) for 1 hours of continuing education credit in jurisdictions which recognize AAVSB RACE approval; however, participants should be aware that some boards have limitations on the number of hours accepted in certain categories or restrictions on certain methods of delivery of continuing education.

For Certified Public Health Professionals (CPH): The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credits for this program.

DISCLOSURE: In compliance with continuing education requirements, all planners and presenters/moderators must disclose all financial relationships, in any amount, with ineligible companies over the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.

CDC, our planners, and presenters/moderators wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use.

CDC did not accept financial or in-kind support from ineligible companies for this continuing education.

Target Audience

• Physicians
• Nurses
• Pharmacists
• Veterinarians
• Physician Assistants
• Health Educators
• Other Clinicians

Additional Information

• Contact Information: coca@cdc.gov
• Support/Funding: Centers for Disease Control and Prevention, Office of Emergency Risk Communication
• Method of Participation: You may participate in the educational activity by viewing the program information above.